A phase 3 trial of IV immunoglobulin for Alzheimer disease

Conclusions:
Participants with mild to moderate AD showed good tolerability of treatment with low-dose human IVIg for 18 months but did not show beneficial effects on cognition or function relative to participants who received placebo.

Clinicaltrials.gov identifier:
NCT00818662.

Classification of evidence:
This study provides Class II evidence that IVIg infusions performed every 2 weeks do not improve cognition or function at 18 months in patients with mild to moderate AD.

Source: Neurology - May 1, 2017 Category: Neurology Authors: Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., Szabo, P., Gelmont, D. M., Fritsch, S., Aisen, P. S., For the Alzheimer's Disease Cooperative Study Tags: Clinical trials Randomized controlled (CONSORT agreement), Alzheimer's disease ARTICLE Source Type: research